QUCY Quantum Cyber N.V.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1874252 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-0.2%
TTM net income YoY18.0%
TTM EPS YoY66.2%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—
Margins
Gross margin64.3%
Operating margin-2,099.9%
Net margin-2,416.0%
FCF margin-1,950.2%
EBITDA margin-2,022.0%
Returns
ROE-462.0%
ROA-149.4%
ROIC (approx.)—
Asset turnover0.06x
Leverage & solvency
Liabilities / assets55.6%
Debt / equity0.00x
Current ratio1.30x
Interest coverage-19.85x
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue11.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $537,080 | $893,991 |
| Cost of revenue | $147,288 | $319,108 |
| Gross profit | $389,792 | $574,883 |
| R&D expense | $4.91M | $5.72M |
| SG&A expense | $5.11M | $6.65M |
| Operating income | -$16.14M | -$18.77M |
| Interest expense | $373,458 | $945,545 |
| Pretax income | -$16.21M | -$21.60M |
| Net income | -$16.21M | -$21.60M |
| EBITDA | -$15.52M | -$18.08M |
| EPS (basic) | -2.70 | -21.91 |
| EPS (diluted) | -2.70 | -21.91 |
| Weighted avg. shares (diluted) | 6.00M | 985,717 |
| Banking | ||
| Net interest income | — | -$39,817 |
| Balance sheet | ||
| Cash & equivalents | $701,602 | $6.24M |
| Receivables | — | $33,577 |
| Inventory | $216,888 | $372,870 |
| Current assets | $4.21M | $8.02M |
| PP&E, net | $1.09M | $1.37M |
| Intangibles | $1.11M | $3.02M |
| Total assets | $5.33M | $13.50M |
| Current liabilities | $4.69M | $6.18M |
| Short-term debt | $956,902 | $1.02M |
| Total liabilities | $4.69M | $7.50M |
| Shareholders' equity | $641,600 | $6.00M |
| Shares outstanding | 9.78M | 2.32M |
| Cash flow statement | ||
| Operating cash flow | -$10.98M | -$17.33M |
| Capital expenditure | $1,216 | $104,949 |
| Free cash flow | -$10.98M | -$17.43M |
| Investing cash flow | -$1.03M | -$198,817 |
| Financing cash flow | $6.76M | $16.79M |
| Depreciation & amortization | $615,720 | $696,629 |
| Stock-based compensation | $1.47M | -$63,117 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.